Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fenghuan Sun

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Nature Genetics|December 10, 2024
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancerYilv Yan, Dongqing Sun, Junjie Hu, et al.
BMC Medicine|December 29, 2022
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trialXinsheng Zhu, Liangdong Sun, Nan Song, et al.
Cell Discovery|November 25, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005)Fenghuan Sun, Lele Zhang, Liangdong Sun, et al.
Signal Transduction and Targeted Therapy|June 13, 2024
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Han Zhang, Zheng Ruan, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Nature Genetics|December 10, 2024
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancerYilv Yan, Dongqing Sun, Junjie Hu, et al.
BMC Medicine|December 29, 2022
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trialXinsheng Zhu, Liangdong Sun, Nan Song, et al.
Cell Discovery|November 25, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005)Fenghuan Sun, Lele Zhang, Liangdong Sun, et al.
Signal Transduction and Targeted Therapy|June 13, 2024
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Han Zhang, Zheng Ruan, et al.
Pageof 2